Novel oxazolinoanthracyclines as tumor cell growth inhibitors-Contribution of autophagy and apoptosis in solid tumor cells death

PLoS One. 2018 Jul 24;13(7):e0201296. doi: 10.1371/journal.pone.0201296. eCollection 2018.

Abstract

Chemical modification of known, effective drugs are one method to improve the chemotherapy of tumors. We reported ability of oxazoline analogs of doxorubicin (O-DOX) and daunorubicin (O-DAU) to induce apoptosis and autophagy in ovarian and liver cancer cells. Reactive oxygen and nitrogen species (ROS and RNS, respectively), together with intracellular calcium-mediated downstream signaling, are essential for the anticancer effect of these new anthracycline analogs. The changes of mitochondrial membrane potential and induction of the ceramide pathway suggests that these compounds induce cell death by apoptosis. In addition, a significant increase of autophagosome formation was observed by fluorescence assay and acridine orange staining, indicating that the new analogs also induce autophagic cell death. Compared to free DOX- and DAU-treated cells, we observed inhibition of colony formation and migration, a time-dependency between ROS/RNS levels and a greater fall in mitochondrial membrane potential. Altogether, our research broadens the base of molecular oxazolinoanthracyclines targets and reveals that derivatives mediated oxidative stress, ceramide production and increase in intracellular calcium level by mitochondria. Furthermore, our data highlight the importance of mitochondria that simultaneously assume the role of activator of autophagy and apoptosis signals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Autophagy / drug effects
  • Cell Line, Tumor
  • Daunorubicin / analogs & derivatives*
  • Daunorubicin / pharmacology*
  • Doxorubicin / analogs & derivatives*
  • Doxorubicin / pharmacology*
  • Growth Inhibitors / chemistry
  • Growth Inhibitors / pharmacology
  • Humans
  • Membrane Potential, Mitochondrial / drug effects
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Oxazoles / chemistry
  • Oxazoles / pharmacology
  • Reactive Oxygen Species / metabolism

Substances

  • Antineoplastic Agents
  • Growth Inhibitors
  • Oxazoles
  • Reactive Oxygen Species
  • Doxorubicin
  • Daunorubicin

Grants and funding

The investigation was supported by a statutory research admitted for Department of Medical Biophysics (B1611000000190.01).